The emerging market for next-generation peptides, short-chain amino acids used in areas including muscle recovery and anti-aging, is expected to generate substantial revenue but with profits spread thinly across many consumer-focused companies rather than concentrated among pharmaceutical giants. This contrasts with earlier peptide successes, such as GLP-1 weight-loss drugs developed by major pharmaceutical firms like Novo Nordisk and Eli Lilly.

A recent survey conducted by Citigroup found that approximately 28 percent of participants had used one of a dozen popular peptides and were willing to spend an average of $90 per month on these products. If this willingness to pay is extrapolated to the entire adult population of the United States, it suggests a potential annual market value of around $80 billion, even within the current unregulated or “grey” market.

Peptides are currently not approved for human consumption and are legally sold as “for research purposes only” through online platforms such as BioLongevity and SwissChems. However, regulatory changes may soon alter this landscape. In July, an advisory panel to the U.S. Food and Drug Administration recommended permitting the domestic production of six out of seven popular peptides, a move that could expand the market substantially. Citigroup’s data indicate that safety concerns and insufficient scientific validation deter roughly half of potential consumers from using peptides, meaning FDA approval could boost user adoption.

Despite the projected scale of the market, economic returns are anticipated to resemble those typical of branded consumer goods rather than blockbuster pharmaceuticals. A key reason is that these newer peptides cannot be patented, as their formulations have been available in scientific literature since the 1990s. This limits barriers to entry and is likely to result in intense competition among a range of companies—including virtual health providers like Ro, LifeMD, and Hims & Hers Health—vying for market share.

Branding and marketing are expected to become crucial competitive factors. Social media and online advertising currently serve as primary channels for consumers discovering grey-market peptides, and marketing expenditures may rise to levels similar to those seen in consumer goods sectors. For context, analysts anticipate that companies like L’Oréal will allocate roughly one-third of their revenue to marketing this year.

Price sensitivity also appears significant, with cost cited as the main reason for discontinuing peptide use. The survey showed that increasing monthly prices from $50 to $150 reduced the potential user base by nearly 70 percent.

Among current market players, Hims holds a competitive edge, having recently acquired its own peptide manufacturing facility. Nevertheless, this advantage could be mitigated if large consumer conglomerates enter the space. As the peptide market evolves, the interplay of regulatory developments, brand-building efforts, and pricing strategies will likely shape the commercial landscape going forward.